EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtVergleichsstudieOpen Access

Middle meningeal artery embolization versus standard of care for chronic subdural hematoma: Meta-analysis of randomized controlled trials

Ali Mortezaei iD, Nadir Al-Saidi, Kiana Yahyaei, Ahmed Abdelsalam, Luis Guada Delgado, Joshua Hanna, Adam A Dmytriw iD, Redi Rahmani, Adib A Abla, Robert M Starke

The Neuroradiology Journal · 2026

DOI: 10.1177/19714009251389579 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift The Neuroradiology Journal, 2026. Verfasst von Ali Mortezaei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Gonabad University of Medical Sciences, Gonabad, Iran. Hauptthemen laut MEDLINE: Hematoma, Subdural, Chronic, Embolization, Therapeutic, Meningeal Arteries, Standard of Care. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The safety and efficacy of the middle meningeal artery embolization (MMAE) in patients with non-acute or chronic subdural hematoma (cSDH) has significant reporting within recent literature, however, mainly in the form of observational data.

Methods

We conducted a systematic review and meta-analysis including all available randomized clinical trials (RCTs) that compared MMAE in addition to standard of care (SOC) versus SOC alone for cSDH. The primary outcome was the rate of recurrence and reoperation. Secondary outcomes included serious adverse events (SAEs), mortality rate, independent ambulation (modified Rankin Scale (mRS) score 0 – 3), and changes in hematoma characteristics at 90 days. The fixed-effect or random-effects model was used based on the significancy of the heterogenicity (I 2 > 50%, P < .1).

Results

Findings showed significant superiority of MMAE over SOC in 90-day recurrence (RR = 0.55, 95% CI = 0.36 – 0.83, P = .0047, I 2 = 43.3%), reoperation within 180 days (RR = 0.38, 95% CI = 0.26–0.56, P < .001, I 2 = 0.0%), ambulatory functional outcome (RR = 1.034, 95% CI = 1.0–1.07, P = .0296, I 2 = 53.9%), SAE at any time (RR = 0.59, 95% CI = 0.38–0.94, P = .025, , I 2 = 0.0%), and 90-day any-cause mortality (RR = 0.29, 95% CI = 0.14–0.6, P = .0008, I 2 = 0.0%). Successful embolization and 30-day embolization-related complications occurred in 99.2% (95% CI = 94.54% – 100%) and 1.18% (95% CI = 0.39% – 2.31%) of patients, respectively. Additionally, subgroup analyses on major and pilot RCTs, comparison of embolic agents, and MMAE adjuvant to surgery versus surgery alone confirmed these findings.

Conclusion

MMAE appears to be safe and effective in the management of cSDH with low recurrence and SAE rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematoma, Subdural, ChronicEmbolization, TherapeuticMeningeal ArteriesStandard of CareHumansRandomized Controlled Trials as TopicRecurrenceTreatment Outcome

Stichwörter der Autor:innen

Middle meningeal artery embolizationchronic subdural hematomanon-acute subdural hematomarandomized controlled trial

Autor:innen und Institutionen

  • Student Research Committee, Gonabad University of Medical Sciences, Gonabad, Iran.
  • College of Medicine, Central Michigan University, Mount Pleasant, MI, USA.
  • School of Medicine, Department of Neurological Surgery, Radiology, Neurosciences, Pharmacology, University of Miami, Miami, FL, USA.
  • Neuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Boston, MA, USA.
  • RADIS Lab and Neurointerventional & Neuroanalytics Collaboration (NAN-C), St. Michael's Hospital, University of Toronto and Toronto Metropolitan University, Toronto, ON.
  • Department of Neurosurgery, University of Louisville, Louisville, KY, USA.

ORCID-Profile: Ali Mortezaei, Adam A Dmytriw

Förderung

  • NCATS NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Mortezaei, A., Al-Saidi, N., Yahyaei, K., Abdelsalam, A., Guada Delgado, L., Hanna, J., Dmytriw, A. A., Rahmani, R., Abla, A. A., & Starke, R. M. (2026). Middle meningeal artery embolization versus standard of care for chronic subdural hematoma: Meta-analysis of randomized controlled trials. The Neuroradiology Journal. https://doi.org/10.1177/19714009251389579

Vancouver

Mortezaei A, Al-Saidi N, Yahyaei K, Abdelsalam A, Guada Delgado L, Hanna J, et al. Middle meningeal artery embolization versus standard of care for chronic subdural hematoma: Meta-analysis of randomized controlled trials. The Neuroradiology Journal. 2026. doi:10.1177/19714009251389579

BibTeX
@article{Mortezaei2026,
  author = {Mortezaei, Ali and Al-Saidi, Nadir and Yahyaei, Kiana and Abdelsalam, Ahmed and Guada Delgado, Luis and Hanna, Joshua and Dmytriw, Adam A and Rahmani, Redi and Abla, Adib A and Starke, Robert M},
  title = {Middle meningeal artery embolization versus standard of care for chronic subdural hematoma: Meta-analysis of randomized controlled trials},
  journal = {The Neuroradiology Journal},
  year = {2026},
  doi = {10.1177/19714009251389579}
}
Kostenlos starten →